These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 16110605)

  • 1. Thymidylate synthase inhibitors.
    Takimoto CH; Diggikar S
    Cancer Chemother Biol Response Modif; 2005; 22():1-18. PubMed ID: 16110605
    [No Abstract]   [Full Text] [Related]  

  • 2. Thymidylate synthase inhibitors.
    Ackland SP; Clarke SJ; Beale P; Peters GJ
    Cancer Chemother Biol Response Modif; 2002; 20():1-36. PubMed ID: 12703198
    [No Abstract]   [Full Text] [Related]  

  • 3. Thymidylate synthase inhibitors.
    Ismail AS; Grem JL
    Cancer Chemother Biol Response Modif; 2001; 19():1-19. PubMed ID: 11686010
    [No Abstract]   [Full Text] [Related]  

  • 4. Antifolates: the next millennium.
    Allegra CJ
    Semin Oncol; 1999 Apr; 26(2 Suppl 6):1-2. PubMed ID: 10598548
    [No Abstract]   [Full Text] [Related]  

  • 5. Thymidylate synthase inhibitors in colorectal cancer.
    Cassidy J
    Semin Oncol; 2000 Oct; 27(5 Suppl 10):83-7. PubMed ID: 11049037
    [No Abstract]   [Full Text] [Related]  

  • 6. MTA, a novel multitargeted antifolate, from preclinical to phase I and beyond: summary and conclusions.
    Calvert H
    Semin Oncol; 1999 Apr; 26(2 Suppl 6):105-8. PubMed ID: 10598564
    [No Abstract]   [Full Text] [Related]  

  • 7. Raltitrexed, a novel folate-based thymidylate synthase inhibitor, for the treatment of acute leukemia: is this drug active against acute myelogenous leukemia?
    Takemura Y; Kobayashi H; Miyachi H
    Int J Hematol; 2000 Jul; 72(1):112-4. PubMed ID: 10979221
    [No Abstract]   [Full Text] [Related]  

  • 8. Determinants of the therapeutic efficacy of thymidylate synthase inhibitors.
    Peters GJ; Kuiper CM; van Triest B; Backus H; van der Wilt CL; van Laar JA; Jansen G; van Groeningen CJ; Pinedo HM
    Adv Exp Med Biol; 1998; 431():699-704. PubMed ID: 9598155
    [No Abstract]   [Full Text] [Related]  

  • 9. Inhibition of thymidylate synthase: biochemical pharmacology of drugs with activity in colorectal cancer.
    Jackman AL
    Tumori; 1997; 83(1 Suppl):S65-6. PubMed ID: 9154072
    [No Abstract]   [Full Text] [Related]  

  • 10. Cell death in response to antimetabolites directed at thymidylate synthase.
    Barbour KW; Berger FG
    Cancer Chemother Pharmacol; 2008 Feb; 61(2):189-201. PubMed ID: 17396263
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thymidylate synthase inhibitors.
    Ackland SP; Beale P; Peters GJ
    Cancer Chemother Biol Response Modif; 2003; 21():1-28. PubMed ID: 15338738
    [No Abstract]   [Full Text] [Related]  

  • 12. Sequence-based identification of specific drug target regions in the thymidylate synthase enzyme family.
    Ferrari S; Losasso V; Costi MP
    ChemMedChem; 2008 Mar; 3(3):392-401. PubMed ID: 18270995
    [No Abstract]   [Full Text] [Related]  

  • 13. Introduction.
    ;
    Invest New Drugs; 2005 Dec; 23(6):511. PubMed ID: 16391895
    [No Abstract]   [Full Text] [Related]  

  • 14. Pemetrexed: new indication. Untreated non-small cell lung cancer: just another cytotoxic drug. No better than the gemcitabine-cisplatin combination with a different safety profile, as is the case for other cytotoxic drugs.
    Prescrire Int; 2009 Jun; 18(101):114. PubMed ID: 19637425
    [No Abstract]   [Full Text] [Related]  

  • 15. An update on thymidylate synthase inhibitors.
    Hughes A; Calvert H
    Ann Oncol; 1999 Oct; 10(10):1137-9. PubMed ID: 10586328
    [No Abstract]   [Full Text] [Related]  

  • 16. Involvement of gene polymorphisms of thymidylate synthase in gene expression, protein activity and anticancer drug cytotoxicity using the NCI-60 panel.
    Nief N; Le Morvan V; Robert J
    Eur J Cancer; 2007 Mar; 43(5):955-62. PubMed ID: 17317154
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel therapeutic developments other than EGFR and VEGF inhibition in colorectal cancer.
    Wilson RH
    Oncologist; 2006 Oct; 11(9):1018-24. PubMed ID: 17030644
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Pharmacogenetic studies on the prediction of efficacy and toxicity of fluoropyrimidine-based adjuvant therapy in colorectal cancer].
    Kralovánszky J; Adleff V; Hitre E; Pap E; Réti A; Komlósi V; Budai B
    Magy Onkol; 2007; 51(2):113-25. PubMed ID: 17660867
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thymidylate synthase expression pattern, expression level and single nucleotide polymorphism are predictors for disease-free survival in patients of colorectal cancer treated with 5-fluorouracil.
    Fernández-Contreras ME; Sánchez-Prudencio S; Sánchez-Hernández JJ; García de Paredes ML; Gisbert JP; Roda-Navarro P; Gamallo C
    Int J Oncol; 2006 May; 28(5):1303-10. PubMed ID: 16596248
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Do thymidylate synthase gene promoter polymorphism and the C/G single nucleotide polymorphism predict effectiveness of adjuvant 5-fluorouracil-based chemotherapy in stage III colonic adenocarcinoma?
    Prall F; Ostwald C; Schiffmann L; Barten M
    Oncol Rep; 2007 Jul; 18(1):203-9. PubMed ID: 17549369
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.